PEPTIDE DERIVATIVE

• US 20120094898A1
• Filed: 10/12/2011
• Published: 04/19/2012
• Est. Priority Date: 10/13/2010
• Status: Abandoned Application

• Current Assignee: Takeda Pharmaceutical Company Limited
• Original Assignee: Takeda Pharmaceutical Company Limited
• Inventors: Asami, Taiji, Nishizawa, Naoki, Kanematsu, Yoko
• Application Number:
  US13/271,763
• Publication Number:
  US 20120094898A1
• Time in Patent Office: Days
• US Class Current: 514/4.9
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: C07K 14/575 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695

Abstract

The present invention relates to a peptide derivative selected from the group consisting of

• PEG20k(AL)-β-Ala-Tyr-Nal(1)-Leu-Phe-Arg-Pro-Arg-Asn-NH₂,
• PEG20k(AL)-β-Ala-Tyr-Nal(2)-Leu-Phe-Arg-Pro-Arg-Asn-NH₂,
• PEG20k(AL)-NpipAc-Tyr-Nal(2)-Leu-Phe-Arg-Pro-Arg-Asn-NH₂,
• PEG20k(AL)-NpipAc-Tyr-Nal(2)-Leu-Phe-Arg-Ala-Arg-Asn-NH₂,
• PEG20k(AL)-PEG(2)-Tyr-Nal(2)-Leu-Phe-Arg-NMeAla-Arg-Asn-NH₂,
• PEG20k(AL)-Pic(4)-Tyr-Nal(2)-Leu-Phe-Arg-NMeAla-Arg-Asn-NH₂,
• PEG20k(AL)-Acp-Tyr-Nal(2)-Leu-Phe-Arg-NMeAla-Arg-Asn-NH₂, and
• PEG20k(AL)-β-Ala-Tyr-Nal(2)-Leu-Pya(4)-Arg-Pro-Arg-Asn-NH₂;
  or a salt thereof.

Claims

1. A peptide derivative selected from the group consisting of

PEG20k(AL)-β

-Ala-Tyr-Nal(1)-Leu-Phe-Arg-Pro-Arg-Asn-NH₂,

PEG20k(AL)-β

-Ala-Tyr-Nal(2)-Leu-Phe-Arg-Pro-Arg-Asn-NH₂,

PEG20k(AL)-NpipAc-Tyr-Nal(2)-Leu-Phe-Arg-Pro-Arg-Asn-NH₂,

PEG20k(AL)-NpipAc-Tyr-Nal(2)-Leu-Phe-Arg-Ala-Arg-Asn-NH₂,

PEG20k(AL)-PEG(2)-Tyr-Nal(2)-Leu-Phe-Arg-NMeAla-Arg-Ash-NH₂,

PEG20k(AL)-Pic(4)-Tyr-Nal(2)-Leu-Phe-Arg-NMeAla-Arg-Asn-NH₂,

PEG20k(AL)-Acp-Tyr-Nal(2)-Leu-Phe-Arg-NMeAla-Arg-Asn-NH₂, and

PEG20k(AL)-β

-Ala-Tyr-Nal(2)-Leu-Pya(4)-Arg-Pro-Arg-Asn-NH₂;

or a salt thereof.

5. A medicament comprising the peptide derivative or a salt thereof of claim 1.

6. The medicament according to claim 5, which is a neuromedin U receptor agonist.

7. The medicament according to claim 5, which is an anorectic agent.

8. The medicament according to claim 5, which is an agent for preventing or treating obesity.

9. A method for preventing or treating obesity, comprising administering to a mammal an effective amount of the peptide derivative or a salt thereof of claim 1.

10. A method for activating a neuromedin U receptor in a mammal, comprising administering to the mammal an effective amount of the peptide derivative or a salt thereof of claim 1.

11. A method for attenuating food intake in a mammal, comprising administering to the mammal an effective amount of the peptide derivative or a salt thereof of claim 1.

12. Use of the peptide derivative or a salt thereof of claim 1 for producing an agent for preventing or treating obesity.

13. Use of the peptide derivative or a salt thereof of claim 1 for producing an anorectic agent.

14. The peptide derivative or a salt thereof of claim 1 for preventing or treating obesity.

15. The peptide derivative or a salt thereof of claim 1 for attenuating food intake.

2. PEG20k(AL)-NpipAc-Tyr-Nal(2)-Leu-Phe-Arg-Pro-Arg-Asn-NH₂, or a salt thereof.

3. PEG20k(AL)-NpipAc-Tyr-Nal(2)-Leu-Phe-Arg-Ala-Arg-Asn-NH₂, or a salt thereof.

4. PEG20k(AL)-Pic(4)-Tyr-Nal(2)-Leu-Phe-Arg-NMeAla-Arg-Asn-NH₂, or a salt thereof.